NEMODENCT07926867
A Pilot Multicentric Open Study Assessing the Efficacy and Safety of NEMOlizumab in Patients ≥ 12yo With Dystrophic Epidermolysis Bullosa
StatusNot Yet Recruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
To study the efficacy of Nemolizumab on pruritus in patients > 12yo with DEB after 4 weeks of treatment, in a multicentric, prospective, and open pilot study.
Timeframe: 4 weeks
Secondary (1)
To describe the evolution of the following efficacy and health outcomes measures after 24 weeks of treatment
Arms and interventions
Nemolizumab will be administered as a 60 mg loading dose (two 30 mg injections) at Day 0, followed bExperimental
Neolizumab
Drugs: Neolizumab
Sites
4 sites in 1 country